Research programme: phosphodiesterase 7 inhibitors - Omeros

Drug Profile

Research programme: phosphodiesterase 7 inhibitors - Omeros

Alternative Names: OMS 527; PDE7 inhibitors - Omeros; Type 7 cyclic nucleotide phosphodiesterase inhibitors - Omeros

Latest Information Update: 10 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asubio Pharma; Omeros Corporation
  • Developer National Institute on Drug Abuse; Omeros Corporation; The Parkinsons Institute and Clinical Center
  • Class
  • Mechanism of Action Type 7 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Drug abuse; Impulse control disorders; Movement disorders

Most Recent Events

  • 10 May 2017 Omeros Corporation plans a clinical trial for OMS 527
  • 10 May 2017 Preclinical development is ongoing (Omeros Corporation pipeline, May 2017)
  • 10 May 2016 Omeros has patent protection for phosphodiesterase-7 inhibitors in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top